Biotech and PharmaBluebird Bio Stock Is Sliding. The Biotech Plans a Share Offering. Jan. 18, 2023 at 10:40 a.m. ETby Barron's Biotech and PharmaBluebird Bio Gets FDA Approval for $3 Million Gene Therapy, Breaking Its Own Price Record ...
BLUE Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced -64.54% bluebird bio, Inc. price and volume Combination chart with 2 data series. Chart represents bluebird bio, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y...
Get the latest bluebird bio Inc. (BLUE) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
Bluebird Biowill sell itself to private equity firms Carlyle and SK Capital for about $30 million, thecompany saidFriday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money. Bluebird’s shareholders will ...
The average bluebird bio price target of $21.33 implies upside potential of 62.3%. Shares have declined about 63.2% over the past year. Related News:Square’s Q3 Results Miss the MarkUber Posts Mixed Q3 Results; Shares DipPinterest Post Stellar Q3 Results Continue Reading Latest News Feed ‘...
Skip to main content Get the best of TheStreet to your inbox SUBSCRIBE TECH Retail INVESTING MARKETS PERSONAL FINANCE CRYPTO PRO Investing Bitcoin Cannabis Cryptocurrency ETFs Earnings Fixed Income Funds Futures Options Rating REITs Stocks
Net loss per share - basic and diluted: $ (2.94 ) $ (3.73 ) $ (6.89 ) $ (10.27 ) Weighted-average number of common shares used in computing net loss per share - basic and diluted: 66,251 55,292 60,762 55,139 bluebird bio, Inc...
to issue and sell from time to time through Xxxxxxxxx LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.01 per share (the “Common Shares”), having an aggregate offering price of up to $125,000,000 on the terms set forth in...
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, ...
Bluebird Bio Company Info Bluebird Bio is a development-stage biotechnology company focused on gene therapy, gene editing, and cancer immunotherapy. News & Analysis The Fool has written over 300 articles on Bluebird Bio. Featured Article Is Bluebird Bio Stock a Buy? It won't be easy for the...